公开(公告)号：JP2002322068A

公开(公告)日：2002-11-08

申请号：JP2001365282

申请日：2001-11-29

申请人： JAPAN SCIENCE & TECH CORP ,  SAKANAKA MASAHIRO ,  HASHIMOTO KOJI

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  HATA RYUJI ,  UNO HIDEMITSU ,  KURAMOTO MAKOTO ,  HASHIMOTO KOJI ,  MITSUDA KENSHO

IPC分类号： A61K31/704 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P13/00 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P31/18 ,  A61P37/02 ,  A61P43/00 ,  C07J9/00

摘要： PROBLEM TO BE SOLVED: To provide an efficacious intravenous preparations, skin care preparations or medicinal compositions comprising ginsenoside derivatives, in particular, dihydroginsenoside Rb1 , and useful in promoting vascular regeneration and reconstruction or preventing, treating and curing diseases or pathological conditions causing blood flow failures, and to obtain the ginsenoside derivatives, in particular, dihydroginsenoside Rb1 , which are useful in preventing, treating and curing diseases or pathological conditions causing blood flow failures via the activation of a transcription factor STAT5 and/or a transcription factor HIF-1. SOLUTION: The intravenous preparations, skin care preparations or medicinal compositions comprise ginsenoside derivatives, in particular, dihydroginsenoside Rb1 , and are useful in promoting vascular regeneration and reconstruction or preventing, treating and curing diseases or pathological conditions causing blood flow failures. The medicinal compositions comprise ginsenosides, such as dihydroginsenoside Rb1 , and are particularly useful in preventing, treating and curing diseases or pathological conditions causing blood flow failures via the activation of a transcription factor STAT5 and/or a transcription factor HIF-1.

公开(公告)号：JP2002249498A

公开(公告)日：2002-09-06

申请号：JP2001044818

申请日：2001-02-21

申请人： JAPAN SCIENCE & TECH CORP ,  SAKANAKA MASAHIRO

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  NAKADA KIMIHIKO ,  UNO HIDEMITSU ,  KURAMOTO MAKOTO

IPC分类号： A01G31/00 ,  A01N45/00 ,  A61K8/00 ,  A61K8/63 ,  A61K31/704 ,  A61P1/02 ,  A61P9/10 ,  A61P17/00 ,  A61P17/02 ,  A61P17/14 ,  A61P25/00 ,  A61P43/00 ,  A61Q5/00 ,  A61Q7/00 ,  C05G3/00 ,  C07J17/00 ,  A23K1/16 ,  A61K7/00 ,  A61K7/06

摘要： PROBLEM TO BE SOLVED: To provide preparations for intravenous administration, liniments for the skin and membranes, and other skin and membrane care preparations or make-up preparations and fertilizing components, based on new ginesenosides derivatives especially dihydroxyginesenoside Rb1 , or epoxyginesenoside Rb1 , which is useful as an antiapoptosis agent, anagenetic and reconstructive accelerating agent for dermal tissues or an accelerating agent for healing wounds. SOLUTION: This pharmaceutical preparation is based on a ginesenoside derivative especially dihydroxyginesenoside Rb1 or epoxy ginesenoside Rb1 to constitute preparations for intravenous administration, membrane and skin care liniments or make-up preparations. This preparation is especially effective to counteract aspects of aging in the skin or membrane, as an anagenetic and reconstructive promoter involved in incised wounds, open wounds, bites and defects, an accelerating agent for healing wounds or effective also for the prevention, treatment or therapy of diseases associated with apoptosis. Another plant or animal growth regulating preparation includes a ginesenocide derivative, especially dihydroxyginesenoside Rb1 or epoxyginesenoside Rb1 .

公开(公告)号：JP2001010972A

公开(公告)日：2001-01-16

申请号：JP18515599

申请日：1999-06-30

申请人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  SATO KOJI

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  SATO KOJI ,  MORITA FUMIO ,  SADAMOTO YASUTAKA

IPC分类号： A61K38/00 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P25/00 ,  A61P27/02 ,  A61P37/00 ,  A61P43/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505

摘要： PROBLEM TO BE SOLVED: To obtain the subject medical composition protecting cells by including peptides relating to prosaposin having a specific partial amino acid sequence to promote expression of apoptosis inhibiting gene Bcl-xL. SOLUTION: This medical composition includes peptides relating to prosaposin at least having partial amino acid sequence of formula: Leu-Ile-Xaa-Asn-Asn-Xaa (Xaa is an optional amino acid), (as preferable examples, a peptide expressed by LSELIINNATEELLIKGL, etc.), or their derivatives. The preferable concentration of extracellular fluid of the peptides relating to prosaposin or their derivatives is

公开(公告)号：JP2002255826A

公开(公告)日：2002-09-11

申请号：JP2001052925

申请日：2001-02-27

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  OHASHI YUICHI ,  YAMAGUCHI MASAHIKO ,  UNO TOSHIHIKO ,  TATEMATSU YOSHIYUKI

IPC分类号： C07H15/20 ,  A61K9/08 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61P27/02

摘要： PROBLEM TO BE SOLVED: To provide an effective instillation preparation, keratoconjunctiva external preparation, instillation composition or medicinal composition which comprises a ginsenoside derivative, especially dihydroginsenoside Rb1 , useful as an agent for stimulating the generation-reconstruction of ocular tissues, especially keratoconjunctiva, or as an agent for stimulating the recovery of wounds. SOLUTION: This instillation preparation, keratoconjunctiva external preparation, instillation composition or medicinal composition comprises a ginsenoside derivative, especially dihydroginsenoside Rb1 , and is especially useful for improving the cornea or conjunctiva-ageing syndromes of ocular tissues, stimulating the regeneration and reconstruction of tissues after the wound or deficiency of keratoconjunctiva, stimulating the wound cure of the keratoconjunctiva, or preventing or treating diseases causing cell death.

公开(公告)号：JP2002201134A

公开(公告)日：2002-07-16

申请号：JP2000402639

申请日：2000-12-28

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  NAKADA KIMIHIKO

IPC分类号： A01G7/06 ,  A61K8/00 ,  A61K8/36 ,  A61K8/365 ,  A61K8/368 ,  A61K8/64 ,  A61K31/5578 ,  A61K38/46 ,  A61K45/00 ,  A61P1/02 ,  A61P17/00 ,  A61P17/02 ,  A61P17/14 ,  A61P25/00 ,  A61P43/00 ,  A61Q5/00 ,  A61Q11/00 ,  C07C59/46 ,  G01N33/15 ,  G01N33/48 ,  G01N33/50 ,  A61K7/00

摘要： PROBLEM TO BE SOLVED: To provide an isocarbacyclin group having inhibitory actions on Bax expression useful as an antiapoptotic agent and to further obtain an effective pharmaceutical preparation for intravenous administration, a skin care preparation, a mucosal preparation for external use or a cosmetic of an isocarbacyclin group or a prosaposin-related peptide group useful as a biotissue regeneration reconstruction promoter or a wound curing promoter. SOLUTION: This antiapoptotic agent comprises the isocarbacyclin group and the pharmaceutical composition is especially useful for prophylaxis, treatment or therapy of diseases causing apoptosis through expression inhibition of the Bax. The pharmaceutical preparation for intravenous injection, mucosal preparation for external use, skin care preparation or cosmetic comprises the isocarbacyclin group or prosaposin-related peptide group and is especially useful for promoting tissue regeneration and reconstruction after incised wounds, open wounds, bites or coloboma of the skin or mucous membranes or promoting wound curing.

公开(公告)号：JP2003225084A

公开(公告)日：2003-08-12

申请号：JP2001374509

申请日：2001-12-07

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  HASHIMOTO KOJI ,  HACHIMAN YOKO ,  TANAKA JUNYA ,  UNO HIDEMITSU ,  KURAMOTO MAKOTO ,  HATA RYUJI

IPC分类号： G01N33/50 ,  A01N1/00 ,  A01N1/02 ,  A01N45/00 ,  A01N65/00 ,  A61K31/704 ,  A61K36/18 ,  A61P35/00 ,  C12N1/04 ,  C12N5/071 ,  C12Q1/02 ,  C12R1/91 ,  G01N33/15 ,  A61K35/78

摘要： PROBLEM TO BE SOLVED: To provide an additive composition for freezing non-germ cells or a non-germ tissue, or a composition selectively damaging tumor cells or immortalized cells by refrigerating or freezing them. SOLUTION: The additive composition containing ginsenosides, their metabolites or salts used for freezing the non-germ cells or non-germ tissue can be used as the composition for freezing preservation of the non-germ cells such as skin keratinocytes, etc., or non-tumor cells and the composition for selectively damaging the tumor cells or immortalized cells by refrigerating or freezing them. Therefore, it can be applied as a medicinal composition for the prevention, treatment and therapy of malignant tumor. Also, to evade a mad cow disease issue, it can be applied for a method for culturing cells or a tissue for transplanting such as the skin keratinocyte (epidermal keratinized cells) by adding a porcine brain extract or porcine hypothalmus extract to a serum-free medium, and for a plant growth-adjusting composition to protect a plant from a cool weather damage or cold stress. COPYRIGHT: (C)2003,JPO

公开(公告)号：JP2002316929A

公开(公告)日：2002-10-31

申请号：JP2001119047

申请日：2001-04-18

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA

IPC分类号： A61K8/00 ,  A61K8/30 ,  A61K8/44 ,  A61K31/198 ,  A61K45/00 ,  A61P17/14 ,  A61P17/16 ,  A61P25/30 ,  A61P43/00 ,  A61Q5/00 ,  A61Q19/00 ,  C12N5/00 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  A23K1/16 ,  A61K7/00 ,  A61K7/06 ,  A61K7/48

摘要： PROBLEM TO BE SOLVED: To provide L-serine or glycine having promoting actions on Bcl-w expression and useful as an antiapoptotic agent and a skin care preparation, a mucosal preparation for external use or a cosmetic composed of the L-serine and/or glycine. SOLUTION: This antiapoptotic agent comprises the L-serine and/or glycine and the pharmaceutical composition is especially useful for prophylaxis, treatment and therapy of diseases in peripheral tissues causing the apoptosis through promotion of the Bcl-w expression. The mucosal preparation for external use, skin care preparation or cosmetic comprises the L-serine and/or glycine and is useful especially for ameliorating aging symptoms of the skin or mucous membrane or promoting wound healing.

公开(公告)号：JP2001139483A

公开(公告)日：2001-05-22

申请号：JP2000227968

申请日：2000-06-21

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  MAEDA SHINJI ,  TANAKA JUNYA ,  NAKADA KIMIHIKO

IPC分类号： A61K31/704 ,  A61K36/25 ,  A61P7/04 ,  A61P9/10 ,  A61P13/02 ,  A61P13/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/28 ,  A61P43/00 ,  C07J17/00 ,  A61K35/78

摘要： PROBLEM TO BE SOLVED: To provide an effective preparation for the administration of a ginseng, its essence, ginseng component, their metabolites or their salts useful as a brain cell-protecting agent or nerve cell injury-treating agent, and especially useful for the prevention and treatment of brain/nerve diseases, heart diseases, etc. SOLUTION: This protecting agent for brain cells or nerve cells consists of a medicinal composition consisting of preferably a low concentration ginseng, its essence, ginseng components, their metabolites or their salts, and accelerates the expression of a brain cell death-inhibitory gene product, BC1-XL protein, or has an activity, of inhibiting apoptosis or apoptosis like cell death. Further, preferably an orally administering preparation or an intravenously administering preparation consisting preferably of a low concentration ginseng, its essence, ginseng components, their metabolites or their salts, e.g. a red ginseng powder or its components is provided.

公开(公告)号：JP2000302798A

公开(公告)日：2000-10-31

申请号：JP34085099

申请日：1999-11-30

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  SATO KOJI

IPC分类号： A61K9/08 ,  A61K31/00 ,  A61K31/704 ,  A61P9/00 ,  A61P25/00 ,  A61P43/00 ,  C07J9/00 ,  C07J17/00

摘要： PROBLEM TO BE SOLVED: To obtain the subject composition capable of protecting a damaged brain for a long period of time by showing excellent promoting action on cerebral blood vessel reproduction and restructuring by intravenous administration after apoplexy and inhibiting secondary denaturation of nerve tissue by making the composition include ginsenoside Rb1. SOLUTION: This parenteral administration preparation contains ginsenoside Rb1 (compound of the formula) or its metabolic product. Preferably the parenteral preparation contains the active ingredient in a low concentration. To be more concrete, the extracellular fluid concentration is preferably =0.1 mg, preferably >=1 mg, more preferably >=10 mg and its upper limit is

公开(公告)号：JP2000191539A

公开(公告)日：2000-07-11

申请号：JP36556098

申请日：1998-12-22

申请人： JAPAN SCIENCE & TECH CORP

发明人： SAKANAKA MASAHIRO ,  TANAKA JUNYA ,  SATO KOJI

IPC分类号： C07J13/00 ,  A61K9/08 ,  A61K31/00 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/704 ,  A61K31/715 ,  A61P9/00 ,  A61P9/02 ,  A61P9/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/16 ,  A61P25/28 ,  A61P37/00 ,  C07J17/00

摘要： PROBLEM TO BE SOLVED: To obtain the subject compound for accelerating expression of cell death suppressing gene product Bcl-xL by containing ginsenoside Rb1. SOLUTION: This protective agent for brain cells and nerve cells is brought to contain ginsenoside Rb1 (a compound expressed by the formula). As a medicinal composition, a formulation for intravenous injections is preferable. The concentration of ginsenoside Rb1 is preferably a low concentration, particularly the concentration of an extracellular fluid is =0.1 mg, preferably 1 mg to 1 g, more preferably 10 mg to 0.1 g.